The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.
The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
The company said it anticipates $19.2 million in revenues for full-year 2019, which would miss the consensus Wall Street estimate of $19.4 million.
The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.
Though the firm's top-line figures fell just shy of analysts' estimates, its installed base of ePlex analyzers grew 49 percent year over year.
Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.
Revenues of $850.5 million beat the company's prior revenue guidance, as well as the consensus Wall Street estimate.
Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.
Total revenues of $36.6 million include product and service revenues, which are expected to be about $33.6 million and would be a 42 percent increase year over year.
The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
The multistate rural health system will adopt Color technology to move to NGS and enhance online engagement for its Imagenetics clinical genomics program.
News items for the week of Jan. 6. 2020.
As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.
Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
The group wants the agency to allow labs to discuss gene-drug relationships with "adequate evidence" in test reports and hold a public meeting.
The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.
The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.
The new complaints add to related patent suits Illumina filed against BGI last year in the US, Germany, Switzerland, and Turkey.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.